ID   CEAM1_RAT               Reviewed;         519 AA.
AC   P16573; Q63093;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2016, sequence version 4.
DT   02-OCT-2024, entry version 200.
DE   RecName: Full=Carcinoembryonic antigen-related cell adhesion molecule 1 {ECO:0000250|UniProtKB:P13688};
DE   AltName: Full=ATP-dependent taurocolate-carrier protein;
DE   AltName: Full=Cell-CAM 105 {ECO:0000303|PubMed:8504806};
DE            Short=C-CAM 105;
DE   AltName: Full=Ecto-ATPase {ECO:0000303|PubMed:2527235};
DE   AltName: Full=GP110 {ECO:0000303|PubMed:8536699};
DE   AltName: Full=pp120;
DE   AltName: CD_antigen=CD66a;
DE   Flags: Precursor;
GN   Name=Ceacam1 {ECO:0000312|RGD:67396};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A) (ISOFORM 1), AND PROTEIN SEQUENCE OF
RP   50-68.
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=2527235; DOI=10.1016/s0021-9258(18)71694-3;
RA   Lin S.-H., Guidotti G.;
RT   "Cloning and expression of a cDNA coding for a rat liver plasma membrane
RT   ecto-ATPase. The primary structure of the ecto-ATPase is similar to that of
RT   the human biliary glycoprotein I.";
RL   J. Biol. Chem. 264:14408-14414(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B) (ISOFORM 2), AND VARIANTS SER-49;
RP   THR-55; VAL-70; THR-73; GLY-74; LEU-75; ASN-76; SER-86; THR-88; GLN-90;
RP   GLU-92; VAL-99; GLY-118; PRO-119; ILE-125 AND LYS-127.
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=1637321; DOI=10.1042/bj2850047;
RA   Culic O., Huang Q., Flanagan D., Hixon D., Lin S.-H.;
RT   "Molecular cloning and expression of a new rat liver cell-CAM105 isoform.
RT   Differential phosphorylation of isoforms.";
RL   Biochem. J. 285:47-53(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-454 (ALLELE A) (ISOFORM 1).
RC   TISSUE=Intestine;
RX   PubMed=8240240; DOI=10.1042/bj2950427;
RA   Cheung P.H., Culic O., Qiu Y., Earley K., Thompson N., Hixson D.C.,
RA   Lin S.-H.;
RT   "The cytoplasmic domain of C-CAM is required for C-CAM-mediated adhesion
RT   function: studies of a C-CAM transcript containing an unspliced intron.";
RL   Biochem. J. 295:427-435(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B) (ISOFORM 2), AND VARIANTS SER-49;
RP   THR-55; VAL-70; THR-73; GLY-74; LEU-75; ASN-76; SER-86; THR-88; GLN-90;
RP   GLU-92; VAL-99; GLY-118; PRO-119; ILE-125 AND LYS-127.
RC   STRAIN=Sprague-Dawley, and Wistar; TISSUE=Liver;
RX   PubMed=8504806; DOI=10.1111/j.1432-1033.1993.tb17860.x;
RA   Edlund M., Gaardsvoll H., Bock E., Oebrink B.;
RT   "Different isoforms and stock-specific variants of the cell adhesion
RT   molecule C-CAM (cell-CAM 105) in rat liver.";
RL   Eur. J. Biochem. 213:1109-1116(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE (ALLELE A) (ISOFORM 2), SUBCELLULAR LOCATION, AND
RP   FUNCTION.
RC   STRAIN=Wistar; TISSUE=Liver;
RX   PubMed=8536699; DOI=10.1111/j.1432-1033.1995.527_b.x;
RA   Lucka L., Cichocka I., Baeumler K., Bechler K., Reutter W.;
RT   "A short isoform of carcinoembryonic-antigen-related rat liver cell-cell
RT   adhesion molecule (C-CAM/gp110) mediates intercellular adhesion. Sequencing
RT   and recombinant functional analysis.";
RL   Eur. J. Biochem. 234:527-535(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND IDENTIFICATION.
RC   STRAIN=Brown Norway;
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE B) (ISOFORM 1), AND VARIANTS
RP   SER-49; THR-55; VAL-70; THR-73; GLY-74; LEU-75; ASN-76; SER-86; THR-88;
RP   GLN-90; GLU-92; VAL-99; GLY-118; PRO-119; ILE-125 AND LYS-127.
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 58-66 AND 119-138.
RX   PubMed=2141577; DOI=10.1016/0014-5793(90)80264-j;
RA   Aurivillius M., Hansen O.C., Lazrek M.B.S., Bock E., Oebrink B.;
RT   "The cell adhesion molecule Cell-CAM 105 is an ecto-ATPase and a member of
RT   the immunoglobulin superfamily.";
RL   FEBS Lett. 264:267-269(1990).
RN   [10]
RP   PARTIAL PROTEIN SEQUENCE, AND SUBCELLULAR LOCATION.
RC   STRAIN=Wistar; TISSUE=Liver;
RX   PubMed=8513803; DOI=10.1111/j.1432-1033.1993.tb17952.x;
RA   Becker A., Lucka L., Kilian C., Kannicht C., Reutter W.;
RT   "Characterisation of the ATP-dependent taurocholate-carrier protein (gp110)
RT   of the hepatocyte canalicular membrane.";
RL   Eur. J. Biochem. 214:539-548(1993).
RN   [11]
RP   PROTEIN SEQUENCE OF 110-138 AND 148-150, AND PHOSPHORYLATION.
RX   PubMed=8420979; DOI=10.1016/s0021-9258(18)53965-x;
RA   Sippel C.J., Suchy F.J., Ananthanarayanan M., Perlmutter D.H.;
RT   "The rat liver ecto-ATPase is also a canalicular bile acid transport
RT   protein.";
RL   J. Biol. Chem. 268:2083-2091(1993).
RN   [12]
RP   HOMODIMERIZATION, AND FUNCTION.
RX   PubMed=2373740; DOI=10.1242/jcs.96.1.17;
RA   Tingstroem A., Blikstad I., Aurivillius M., Obrink B.;
RT   "C-CAM (cell-CAM 105) is an adhesive cell surface glycoprotein with
RT   homophilic binding properties.";
RL   J. Cell Sci. 96:17-25(1990).
RN   [13]
RP   CHARACTERIZATION.
RX   PubMed=1831973; DOI=10.1042/bj2780155;
RA   Lin S.-H., Culic O., Flanagan D., Hixson D.C.;
RT   "Immunochemical characterization of two isoforms of rat liver ecto-ATPase
RT   that show an immunological and structural identity with a glycoprotein
RT   cell-adhesion molecule with Mr 105,000.";
RL   Biochem. J. 278:155-161(1991).
RN   [14]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=8454589; DOI=10.1016/s0021-9258(18)53230-0;
RA   Cheung P.H., Thompson N.L., Earley K., Culic O., Hixson D., Lin S.H.;
RT   "Cell-CAM105 isoforms with different adhesion functions are coexpressed in
RT   adult rat tissues and during liver development.";
RL   J. Biol. Chem. 268:6139-6146(1993).
RN   [15]
RP   ALTERNATIVE SPLICING.
RX   PubMed=8380406; DOI=10.1016/s0021-9258(18)54060-6;
RA   Najjae S.M., Accili D., Philippe N., Jernberg J., Margolis R., Taylor S.I.;
RT   "pp120/ecto-ATPase, an endogenous substrate of the insulin receptor
RT   tyrosine kinase, is expressed as two variably spliced isoforms.";
RL   J. Biol. Chem. 268:1201-1206(1993).
RN   [16]
RP   FUNCTION, PHOSPHORYLATION AT TYR-488 AND SER-503, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF TYR-488 AND 502-THR-SER-503.
RX   PubMed=7518458; DOI=10.1016/s0021-9258(17)32202-0;
RA   Sippel C.J., Fallon R.J., Perlmutter D.H.;
RT   "Bile acid efflux mediated by the rat liver canalicular bile acid
RT   transport/ecto-ATPase protein requires serine 503 phosphorylation and is
RT   regulated by tyrosine 488 phosphorylation.";
RL   J. Biol. Chem. 269:19539-19545(1994).
RN   [17]
RP   PHOSPHORYLATION AT TYR-488 BY INSR, AND MUTAGENESIS OF TYR-488 AND SER-503.
RX   PubMed=7626603; DOI=10.1021/bi00029a009;
RA   Najjar S.M., Philippe N., Suzuki Y., Ignacio G.A., Formisano P., Accili D.,
RA   Taylor S.I.;
RT   "Insulin-stimulated phosphorylation of recombinant pp120/HA4, an endogenous
RT   substrate of the insulin receptor tyrosine kinase.";
RL   Biochemistry 34:9341-9349(1995).
RN   [18]
RP   FUNCTION, AND MUTAGENESIS OF TYR-488; SER-503 AND TYR-513.
RX   PubMed=7592607; DOI=10.1074/jbc.270.41.24073;
RA   Formisano P., Najjar S.M., Gross C.N., Philippe N., Oriente F.,
RA   Kern-Buell C.L., Accili D., Gorden P.;
RT   "Receptor-mediated internalization of insulin. Potential role of pp120/HA4,
RT   a substrate of the insulin receptor kinase.";
RL   J. Biol. Chem. 270:24073-24077(1995).
RN   [19]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=7774714; DOI=10.1016/0014-5793(95)00436-d;
RA   Olsson H., Wikstroem K., Kjellstroem G., Obrink B.;
RT   "Cell adhesion activity of the short cytoplasmic domain isoform of C-CAM
RT   (C-CAM2) in CHO cells.";
RL   FEBS Lett. 365:51-56(1995).
RN   [20]
RP   SUBCELLULAR LOCATION, AND HOMODIMERIZATION.
RX   PubMed=9003371; DOI=10.1042/bj3200847;
RA   Hunter I., Sawa H., Edlund M., Obrink B.;
RT   "Evidence for regulated dimerization of cell-cell adhesion molecule (C-CAM)
RT   in epithelial cells.";
RL   Biochem. J. 320:847-853(1996).
RN   [21]
RP   DOMAIN, AND HOMODIMERIZATION.
RX   PubMed=8831574; DOI=10.1006/excr.1996.0285;
RA   Wikstroem K., Kjellstroem G., Obrink B.;
RT   "Homophilic intercellular adhesion mediated by C-CAM is due to a domain 1-
RT   domain 1 reciprocal binding.";
RL   Exp. Cell Res. 227:360-366(1996).
RN   [22]
RP   INTERACTION WITH CALMODULIN, AND REGION.
RX   PubMed=8576129; DOI=10.1074/jbc.271.3.1393;
RA   Edlund M., Blikstad I., Obrink B.;
RT   "Calmodulin binds to specific sequences in the cytoplasmic domain of C-CAM
RT   and down-regulates C-CAM self-association.";
RL   J. Biol. Chem. 271:1393-1399(1996).
RN   [23]
RP   FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF TYR-488; SER-503 AND
RP   TYR-513, AND PHOSPHORYLATION AT TYR-488 BY INSR.
RX   PubMed=9712832; DOI=10.1074/jbc.273.35.22194;
RA   Choice C.V., Howard M.J., Poy M.N., Hankin M.H., Najjar S.M.;
RT   "Insulin stimulates pp120 endocytosis in cells co-expressing insulin
RT   receptors.";
RL   J. Biol. Chem. 273:22194-22200(1998).
RN   [24]
RP   NOMENCLATURE OF ALTERNATIVE SPLICING ISOFORMS.
RX   PubMed=11501563; DOI=10.1006/excr.1999.4610;
RA   Beauchemin N., Draber P., Dveksler G., Gold P., Gray-Owen S., Grunert F.,
RA   Hammarstrom S., Holmes K.V., Karlsson A., Kuroki M., Lin S.H., Lucka L.,
RA   Najjar S.M., Neumaier M., Obrink B., Shively J.E., Skubitz K.M.,
RA   Stanners C.P., Thomas P., Thompson J.A., Virji M., von Kleist S.,
RA   Wagener C., Watt S., Zimmermann W.;
RT   "Redefined nomenclature for members of the carcinoembryonic antigen
RT   family.";
RL   Exp. Cell Res. 252:243-249(1999).
RN   [25]
RP   INTERACTION WITH SHC1, FUNCTION, AND MUTAGENESIS OF TYR-488 AND SER-503.
RX   PubMed=11694516; DOI=10.1074/jbc.m108415200;
RA   Poy M.N., Ruch R.J., Fernstrom M.A., Okabayashi Y., Najjar S.M.;
RT   "Shc and CEACAM1 interact to regulate the mitogenic action of insulin.";
RL   J. Biol. Chem. 277:1076-1084(2002).
RN   [26]
RP   TISSUE SPECIFICITY.
RX   PubMed=11994468; DOI=10.4049/jimmunol.168.10.5139;
RA   Singer B.B., Scheffrahn I., Heymann R., Sigmundsson K., Kammerer R.,
RA   Obrink B.;
RT   "Carcinoembryonic antigen-related cell adhesion molecule 1 expression and
RT   signaling in human, mouse, and rat leukocytes: evidence for replacement of
RT   the short cytoplasmic domain isoform by glycosylphosphatidylinositol-linked
RT   proteins in human leukocytes.";
RL   J. Immunol. 168:5139-5146(2002).
RN   [27]
RP   MUTAGENESIS OF SER-503, AND FUNCTION.
RX   PubMed=11850617; DOI=10.1038/ng840;
RA   Poy M.N., Yang Y., Rezaei K., Fernstroem M.A., Lee A.D., Kido Y.,
RA   Erickson S.K., Najjar S.M.;
RT   "CEACAM1 regulates insulin clearance in liver.";
RL   Nat. Genet. 30:270-276(2002).
RN   [28]
RP   PHOSPHORYLATION AT TYR-488 BY EGFR, FUNCTION, MUTAGENESIS OF TYR-488 AND
RP   SER-503, AND INTERACTION WITH EGFR.
RX   PubMed=15467833; DOI=10.1172/jci21786;
RA   Abou-Rjaily G.A., Lee S.J., May D., Al-Share Q.Y., Deangelis A.M.,
RA   Ruch R.J., Neumaier M., Kalthoff H., Lin S.H., Najjar S.M.;
RT   "CEACAM1 modulates epidermal growth factor receptor--mediated cell
RT   proliferation.";
RL   J. Clin. Invest. 114:944-952(2004).
RN   [29]
RP   INTERACTION WITH FASN, MUTAGENESIS OF TYR-488; SER-503 AND TYR-513,
RP   SUBCELLULAR LOCATION, FUNCTION, AND PHOSPHORYLATION AT TYR-488 AND TYR-513
RP   BY INSR.
RX   PubMed=16054098; DOI=10.1016/j.cmet.2005.06.001;
RA   Najjar S.M., Yang Y., Fernstroem M.A., Lee S.J., Deangelis A.M.,
RA   Rjaily G.A., Al-Share Q.Y., Dai T., Miller T.A., Ratnam S., Ruch R.J.,
RA   Smith S., Lin S.H., Beauchemin N., Oyarce A.M.;
RT   "Insulin acutely decreases hepatic fatty acid synthase activity.";
RL   Cell Metab. 2:43-53(2005).
RN   [30]
RP   INTERACTION WITH FLNA, AND REGION.
RX   PubMed=16291724; DOI=10.1242/jcs.02660;
RA   Klaile E., Mueller M.M., Kannicht C., Singer B.B., Lucka L.;
RT   "CEACAM1 functionally interacts with filamin A and exerts a dual role in
RT   the regulation of cell migration.";
RL   J. Cell Sci. 118:5513-5524(2005).
RN   [31]
RP   SUBCELLULAR LOCATION, DOMAIN, INTERACTION WITH PTPN11; PTPN6 AND SRC, AND
RP   SUBUNIT.
RX   PubMed=19948503; DOI=10.1083/jcb.200904150;
RA   Mueller M.M., Klaile E., Vorontsova O., Singer B.B., Obrink B.;
RT   "Homophilic adhesion and CEACAM1-S regulate dimerization of CEACAM1-L and
RT   recruitment of SHP-2 and c-Src.";
RL   J. Cell Biol. 187:569-581(2009).
CC   -!- FUNCTION: [Isoform 1]: Cell adhesion protein that mediates homophilic
CC       cell adhesion in a calcium-independent manner (PubMed:2373740,
CC       PubMed:8454589). Plays a role as coinhibitory receptor in immune
CC       response, insulin action and functions also as an activator during
CC       angiogenesis (PubMed:11850617). Its coinhibitory receptor function is
CC       phosphorylation- and PTPN6 -dependent, which in turn, suppress signal
CC       transduction of associated receptors by dephosphorylation of their
CC       downstream effectors (By similarity). Plays a role in immune response,
CC       of T-cells, natural killer (NK) and neutrophils (By similarity). Upon
CC       TCR/CD3 complex stimulation, inhibits TCR-mediated cytotoxicity by
CC       blocking granule exocytosis by mediating homophilic binding to adjacent
CC       cells, allowing interaction with and phosphorylation by LCK and
CC       interaction with the TCR/CD3 complex which recruits PTPN6 resulting in
CC       dephosphorylation of CD247 and ZAP70 (By similarity). Also inhibits T-
CC       cell proliferation and cytokine production through inhibition of JNK
CC       cascade and plays a crucial role in regulating autoimmunity and anti-
CC       tumor immunity by inhibiting T-cell through its interaction with HAVCR2
CC       (By similarity). Upon natural killer (NK) cells activation, inhibit
CC       KLRK1-mediated cytolysis of CEACAM1-bearing tumor cells by trans-
CC       homophilic interactions with CEACAM1 on the target cell and lead to
CC       cis-interaction between CEACAM1 and KLRK1, allowing PTPN6 recruitment
CC       and then VAV1 dephosphorylation (By similarity). Upon neutrophils
CC       activation negatively regulates IL1B production by recruiting PTPN6 to
CC       a SYK-TLR4-CEACAM1 complex, that dephosphorylates SYK, reducing the
CC       production of reactive oxygen species (ROS) and lysosome disruption,
CC       which in turn, reduces the activity of the inflammasome (By
CC       similarity). Down-regulates neutrophil production by acting as a
CC       coinhibitory receptor for CSF3R by downregulating the CSF3R-STAT3
CC       pathway through recruitment of PTPN6 that dephosphorylates CSF3R (By
CC       similarity). Also regulates insulin action by promoting INS clearance
CC       and regulating lipogenesis in liver through regulating insulin
CC       signaling (PubMed:11850617). Upon INS stimulation, undergoes
CC       phosphorylation by INSR leading to INS clearance by increasing
CC       receptor-mediated insulin endocytosis (PubMed:7592607, PubMed:9712832).
CC       This inernalization promotes interaction with FASN leading to receptor-
CC       mediated insulin degradation and to reduction of FASN activity leading
CC       to negative regulation of fatty acid synthesis (PubMed:16054098,
CC       PubMed:7592607). INSR-mediated phosphorylation also provokes a down-
CC       regulation of cell proliferation through SHC1 interaction resulting in
CC       decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 and
CC       phosphatidylinositol 3-kinase pathways (PubMed:11694516). Functions as
CC       activator in angiogenesis by promoting blood vessel remodeling through
CC       endothelial cell differentiation and migration and in arteriogenesis by
CC       increasing the number of collateral arteries and collateral vessel
CC       calibers after ischemia (By similarity). Also regulates vascular
CC       permeability through the VEGFR2 signaling pathway resulting in control
CC       of nitric oxide production (By similarity). Down-regulates cell growth
CC       in response to EGF through its interaction with SHC1 that mediates
CC       interaction with EGFR resulting in decrease coupling of SHC1 to the
CC       MAPK3/ERK1-MAPK1/ERK2 pathway (PubMed:15467833). Negatively regulates
CC       platelet aggregation by decreasing platelet adhesion on type I collagen
CC       through the GPVI-FcRgamma complex (By similarity). Inhibits cell
CC       migration and cell scattering through interaction with FLNA; interferes
CC       with the interaction of FLNA with RALA (By similarity). Mediates bile
CC       acid transport activity in a phosphorylation dependent manner
CC       (PubMed:7518458). Negatively regulates osteoclastogenesis (By
CC       similarity). {ECO:0000250|UniProtKB:P13688,
CC       ECO:0000250|UniProtKB:P31809, ECO:0000269|PubMed:11694516,
CC       ECO:0000269|PubMed:11850617, ECO:0000269|PubMed:15467833,
CC       ECO:0000269|PubMed:16054098, ECO:0000269|PubMed:2373740,
CC       ECO:0000269|PubMed:7518458, ECO:0000269|PubMed:7592607,
CC       ECO:0000269|PubMed:8454589, ECO:0000269|PubMed:9712832}.
CC   -!- FUNCTION: [Isoform 2]: Cell adhesion proteins that mediates homophilic
CC       cell adhesion in a calcium-independent manner (PubMed:7774714,
CC       PubMed:8536699). Promotes populations of T-cells regulating IgA
CC       production and secretion associated with control of the commensal
CC       microbiota and resistance to enteropathogens (By similarity).
CC       {ECO:0000250|UniProtKB:P31809, ECO:0000269|PubMed:7774714,
CC       ECO:0000269|PubMed:8536699}.
CC   -!- SUBUNIT: Monomer (PubMed:19948503, PubMed:9003371). Oligomer.
CC       Heterodimer. Homodimer (PubMed:19948503). Cis-dimer/oligomer (via Ig-
CC       like C2-type and/or via cytoplasmic domains); induced by trans-
CC       homophilic cell adhesion through an allosteric mechanism transmitted by
CC       the Ig-like V-type domain, and is regulated by intracellular calcium
CC       and calmodulin (PubMed:19948503, PubMed:2373740, PubMed:8831574,
CC       PubMed:9003371). Interacts (via cytoplasmic domain) with calmodulin in
CC       a calcium dependent manner; reduces homophilic cell adhesion through
CC       dissociation of dimer (PubMed:8576129). Isoform 1 interacts (via
CC       cytoplasmic domain) with PTPN11 (preferentially) and PTPN6; cis-
CC       homodimer form is preferred; this interaction is decreased by formation
CC       of isoform 1 / isoform 2 cis-heterodimers and is dependent on the
CC       monomer/dimer equilibrium; this interaction is phosphorylation-
CC       dependent (PubMed:19948503). Isoform 1 interacts with LYN (By
CC       similarity). Isoform 1 interacts (via cytoplasmic domain) with SRC (via
CC       SH2 domain); this interaction is regulated by trans-homophilic cell
CC       adhesion (PubMed:19948503). Isoform 1 interacts (via cytoplasmic
CC       domain) with LCK; mediates phosphorylation at Tyr-488 and Tyr-513
CC       resulting in PTPN6 association. Isoform 1 interacts with PTPN6; this
CC       interaction is phosphorylation-dependent and causes a profound decrease
CC       in TCR stimulation-induced CD247 and ZAP70 phosphorylation. Isoform 1
CC       interacts with TCR/CD3 complex through TCR beta chain and CD3E;
CC       colocalizes at the cell surface and upon stimulation of the TCR/CD3
CC       complex recruits PTPN6 in the TCR/CD3 complex, resulting in
CC       dephosphorylation of CD247 and ZAP70 (By similarity). Isoform 1
CC       interacts (via cytoplasmic domain) with SHC1 (via SH2 domain); SHC1
CC       mediates interaction with INSR or EGFR in a Ser-503 phosphorylation-
CC       dependent manner (PubMed:11694516). Isoform 1 interacts with EGFR; the
CC       interaction is indirect (PubMed:15467833). Isoform 1 interacts with
CC       CSF3R; down-regulates the CSF3R-STAT3 pathway through recruitment of
CC       PTPN6 that dephosphorylates CSF3R. Isoform 1 (phosphorylated form)
CC       interacts with TLR4 and SYK; recruits PTPN6 that dephosphorylates SYK,
CC       reducing the production of reactive oxygen species (ROS) and lysosome
CC       disruption, leading to a reduction of the inflammasome activity (By
CC       similarity). Isoform 1 interacts with FLNA; inhibits cell migration and
CC       cell scattering by interfering with the interaction of FLNA with RALA
CC       (PubMed:16291724). Isoform 1 interacts (via cytoplasmic domain) with
CC       PXN; the interaction is phosphotyrosyl-dependent. Isoform 1 interacts
CC       with KLRK1; recruits PTPN6 that dephosphorylates VAV1. Isoform 1
CC       interacts with CEACAM8 (By similarity). Isoform 1 interacts with FASN;
CC       this interaction is insulin and phosphorylation-dependent; reduces
CC       fatty-acid synthase activity (PubMed:16054098). Interacts (via Ig-like
CC       V-type) with HAVCR2 (via Ig-like V-type); facilitates the maturation
CC       and cell surface expression of HAVCR2 thereby regulating T-cell
CC       tolerance induction. Isoform 2 interacts (via the cytoplasmic domain)
CC       with ANXA2; this interaction is regulated by phosphorylation and
CC       appears in the AIIt complex. Interacts (via Lewis X moieties) with
CC       CD209 (via C-type lectin domain); this interaction is regulated by the
CC       glycosylation pattern of CEACAM1 on cell types and regulates contact
CC       between dendritic cells and neutrophils (By similarity).
CC       {ECO:0000250|UniProtKB:P13688, ECO:0000250|UniProtKB:P31809,
CC       ECO:0000269|PubMed:11694516, ECO:0000269|PubMed:15467833,
CC       ECO:0000269|PubMed:16054098, ECO:0000269|PubMed:16291724,
CC       ECO:0000269|PubMed:19948503, ECO:0000269|PubMed:2373740,
CC       ECO:0000269|PubMed:8576129, ECO:0000269|PubMed:8831574,
CC       ECO:0000269|PubMed:9003371}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000269|PubMed:16054098, ECO:0000269|PubMed:7518458,
CC       ECO:0000269|PubMed:7774714, ECO:0000269|PubMed:8536699,
CC       ECO:0000269|PubMed:9003371, ECO:0000269|PubMed:9712832}; Single-pass
CC       type I membrane protein. Lateral cell membrane
CC       {ECO:0000269|PubMed:7774714}. Apical cell membrane
CC       {ECO:0000269|PubMed:7774714}. Basal cell membrane
CC       {ECO:0000269|PubMed:7774714}. Cell junction
CC       {ECO:0000269|PubMed:19948503, ECO:0000269|PubMed:9003371}. Cell
CC       junction, adherens junction {ECO:0000269|PubMed:19948503}.
CC       Note=Canalicular domain of hepatocyte plasma membranes
CC       (PubMed:8513803). Found as a mixture of monomer, dimer and oligomer in
CC       the plasma membrane. Occurs predominantly as cis-dimers and/or small
CC       cis-oligomers in the cell junction regions (PubMed:19948503). Found as
CC       dimer in the solution (PubMed:9003371). Predominantly localized to the
CC       lateral cell membranes (PubMed:7774714). {ECO:0000269|PubMed:19948503,
CC       ECO:0000269|PubMed:7774714, ECO:0000269|PubMed:8513803,
CC       ECO:0000269|PubMed:9003371}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane
CC       {ECO:0000269|PubMed:7774714, ECO:0000269|PubMed:9003371}; Single-pass
CC       type I membrane protein. Lateral cell membrane
CC       {ECO:0000269|PubMed:7774714}. Apical cell membrane
CC       {ECO:0000269|PubMed:7774714}. Basal cell membrane
CC       {ECO:0000269|PubMed:7774714}. Cell junction
CC       {ECO:0000269|PubMed:19948503}. Cell junction, adherens junction
CC       {ECO:0000269|PubMed:19948503}. Cytoplasmic vesicle, secretory vesicle
CC       {ECO:0000250|UniProtKB:P13688}. Note=Predominantly localized to the
CC       lateral cell membranes (PubMed:7774714). Found as a mixture of monomer,
CC       dimer and oligomer in the plasma membrane. Occurs predominantly as cis-
CC       dimers and/or small cis-oligomers in the cell junction regions
CC       (PubMed:19948503). Co-localizes with ANXA2 in secretory vesicles and
CC       with S100A10/p11 at the plasma membrane (By similarity).
CC       {ECO:0000250|UniProtKB:P13688, ECO:0000269|PubMed:19948503,
CC       ECO:0000269|PubMed:7774714}.
CC   -!- SUBCELLULAR LOCATION: Cell projection, microvillus membrane
CC       {ECO:0000250|UniProtKB:P31809}; Single-pass type I membrane protein
CC       {ECO:0000305}. Apical cell membrane {ECO:0000250|UniProtKB:P31809};
CC       Single-pass type I membrane protein {ECO:0000305}. Note=Localized to
CC       the apical glycocalyx surface (By similarity). Colocalizes with
CC       CEACAM20 at the apical brush border of intestinal cells (By
CC       similarity). {ECO:0000250|UniProtKB:P13688,
CC       ECO:0000250|UniProtKB:P31809}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=For each isoform it exists 2 allelic variants, named a and b.
CC         The allelic variants differ in 16 amino acids in the Ig-like V-type
CC         domain. {ECO:0000305|PubMed:8504806};
CC       Name=1; Synonyms=CEACAM1-4L {ECO:0000303|PubMed:11501563}, C-CAM1,
CC       L-form Cell-CAM105;
CC         IsoId=P16573-1; Sequence=Displayed;
CC       Name=2; Synonyms=CEACAM1-4S {ECO:0000303|PubMed:11501563}, C-CAM2,
CC       S-form Cell-CAM105;
CC         IsoId=P16573-2; Sequence=VSP_002504, VSP_002505;
CC   -!- TISSUE SPECIFICITY: Expressed in epithelia, vessel endothelia,
CC       leukocytes and platelets. Isoform 1 and isoform 2 are highly expressed
CC       in liver and intestine, moderately in lung, and weakly in muscle,
CC       kidney, and spleen (PubMed:8454589). Expressed in granulocytes,
CC       lymphocytes, granulocytes, B cells, and T-cells (PubMed:11994468).
CC       {ECO:0000269|PubMed:11994468, ECO:0000269|PubMed:8454589}.
CC   -!- DOMAIN: Ig-like V-type domain mediates trans-homophilic cell adhesion
CC       through homodimerization and this active process is regulated by
CC       tyrosine kinase, PTPN11 and PTPN6. Ig-like C2-type and/or cytoplasmic
CC       domains mediate cis-dimer/oligomer. {ECO:0000269|PubMed:19948503,
CC       ECO:0000269|PubMed:8831574}.
CC   -!- PTM: [Isoform 1]: Phosphorylated on serine and tyrosine
CC       (PubMed:8420979). Isoform 1 is phosphorylated on tyrosine by Src family
CC       kinases like SRC and LCK and by receptor like CSF3R, EGFR and INSR upon
CC       stimulation (PubMed:15467833, PubMed:16054098, PubMed:7626603,
CC       PubMed:9712832). Phosphorylated at Ser-503; mediates activity.
CC       Phosphorylated at Tyr-488; regulates activity (PubMed:7518458).
CC       Phosphorylated at Tyr-488 by EGFR and INSR upon stimulation; this
CC       phosphorylation is Ser-503-phosphorylation-dependent; mediates cellular
CC       internalization; increases interaction with FASN (PubMed:15467833,
CC       PubMed:16054098, PubMed:7626603, PubMed:9712832). Phosphorylated at
CC       Tyr-488 and Tyr-513 by LCK; mediates PTPN6 association and is regulated
CC       by homophilic ligation of CEACAM1 in the absence of T-cell activation
CC       (By similarity). Phosphorylated at Tyr-513; mediates interaction with
CC       PTPN11 (By similarity). {ECO:0000250|UniProtKB:P13688,
CC       ECO:0000250|UniProtKB:P31809, ECO:0000269|PubMed:15467833,
CC       ECO:0000269|PubMed:16054098, ECO:0000269|PubMed:7518458,
CC       ECO:0000269|PubMed:7626603, ECO:0000269|PubMed:8420979,
CC       ECO:0000269|PubMed:9712832}.
CC   -!- PTM: [Isoform 2]: Phosphorylated on serine and threonine.
CC       {ECO:0000269|PubMed:8420979}.
CC   -!- POLYMORPHISM: There are two different allelic variants of CEACAM1,
CC       named a and b. The allelic variants differ in 16 amino acids in the Ig-
CC       like V-type domain. The sequence shown here, corresponds to allele A.
CC       {ECO:0000269|PubMed:8504806}.
CC   -!- MISCELLANEOUS: [Isoform 1]: Allele a.
CC   -!- MISCELLANEOUS: [Isoform 2]: Allele a. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA16783.1; Type=Miscellaneous discrepancy; Note=Dubious isoform. Probable cloning artifact lacking polyadenylation evidence.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J04963; AAA41104.1; -; mRNA.
DR   EMBL; Z12019; CAA78054.1; -; mRNA.
DR   EMBL; M92848; AAA16783.1; ALT_SEQ; mRNA.
DR   EMBL; X71122; CAA50435.1; -; mRNA.
DR   EMBL; X91137; CAA62577.1; -; mRNA.
DR   EMBL; AC134759; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH473979; EDM08020.1; -; Genomic_DNA.
DR   EMBL; BC061740; AAH61740.1; -; mRNA.
DR   PIR; A44783; A44783.
DR   PIR; S23969; S23969.
DR   PIR; S68177; S68177.
DR   RefSeq; NP_001029032.1; NM_001033860.1. [P16573-1]
DR   RefSeq; NP_001029033.1; NM_001033861.1.
DR   RefSeq; NP_001029034.1; NM_001033862.1. [P16573-2]
DR   RefSeq; NP_113943.1; NM_031755.2.
DR   AlphaFoldDB; P16573; -.
DR   SMR; P16573; -.
DR   MINT; P16573; -.
DR   STRING; 10116.ENSRNOP00000046654; -.
DR   TCDB; 8.A.23.1.4; the basigin (basigin) family.
DR   GlyCosmos; P16573; 15 sites, No reported glycans.
DR   GlyGen; P16573; 15 sites.
DR   iPTMnet; P16573; -.
DR   PhosphoSitePlus; P16573; -.
DR   PaxDb; 10116-ENSRNOP00000046654; -.
DR   Ensembl; ENSRNOT00000051892.7; ENSRNOP00000046654.3; ENSRNOG00000020578.9. [P16573-1]
DR   Ensembl; ENSRNOT00000090629.2; ENSRNOP00000074820.1; ENSRNOG00000020578.9. [P16573-2]
DR   Ensembl; ENSRNOT00060054164; ENSRNOP00060044916; ENSRNOG00060031079. [P16573-1]
DR   Ensembl; ENSRNOT00065056611; ENSRNOP00065046590; ENSRNOG00065032913. [P16573-1]
DR   GeneID; 81613; -.
DR   KEGG; rno:81613; -.
DR   UCSC; RGD:67396; rat. [P16573-1]
DR   AGR; RGD:67396; -.
DR   CTD; 634; -.
DR   RGD; 67396; Ceacam1.
DR   eggNOG; ENOG502RXPD; Eukaryota.
DR   GeneTree; ENSGT01100000263479; -.
DR   InParanoid; P16573; -.
DR   OMA; GDETEWT; -.
DR   OrthoDB; 3033616at2759; -.
DR   TreeFam; TF336859; -.
DR   Reactome; R-RNO-1566977; Fibronectin matrix formation.
DR   Reactome; R-RNO-163125; Post-translational modification: synthesis of GPI-anchored proteins.
DR   Reactome; R-RNO-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-RNO-6798695; Neutrophil degranulation.
DR   PRO; PR:P16573; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Proteomes; UP000234681; Chromosome 1.
DR   Bgee; ENSRNOG00000020578; Expressed in jejunum and 18 other cell types or tissues.
DR   ExpressionAtlas; P16573; baseline and differential.
DR   GO; GO:0005912; C:adherens junction; IDA:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030054; C:cell junction; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; IDA:RGD.
DR   GO; GO:0060170; C:ciliary membrane; ISO:RGD.
DR   GO; GO:0009897; C:external side of plasma membrane; ISO:RGD.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0031528; C:microvillus membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0042101; C:T cell receptor complex; ISO:RGD.
DR   GO; GO:0030133; C:transport vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0003779; F:actin binding; ISO:RGD.
DR   GO; GO:0015125; F:bile acid transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0031005; F:filamin binding; ISO:RGD.
DR   GO; GO:0005130; F:granulocyte colony-stimulating factor receptor binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; IMP:UniProtKB.
DR   GO; GO:0019900; F:kinase binding; ISO:RGD.
DR   GO; GO:0046983; F:protein dimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0019903; F:protein phosphatase binding; ISO:RGD.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; ISO:RGD.
DR   GO; GO:0035325; F:Toll-like receptor binding; ISO:RGD.
DR   GO; GO:0015721; P:bile acid and bile salt transport; IDA:UniProtKB.
DR   GO; GO:0001568; P:blood vessel development; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IDA:UniProtKB.
DR   GO; GO:0098742; P:cell-cell adhesion via plasma-membrane adhesion molecules; IDA:UniProtKB.
DR   GO; GO:0045216; P:cell-cell junction organization; ISO:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProtKB.
DR   GO; GO:0035726; P:common myeloid progenitor cell proliferation; ISS:UniProtKB.
DR   GO; GO:0038158; P:granulocyte colony-stimulating factor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IDA:UniProtKB.
DR   GO; GO:1901143; P:insulin catabolic process; IMP:UniProtKB.
DR   GO; GO:0038016; P:insulin receptor internalization; IDA:UniProtKB.
DR   GO; GO:0045779; P:negative regulation of bone resorption; ISO:RGD.
DR   GO; GO:0001818; P:negative regulation of cytokine production; ISO:RGD.
DR   GO; GO:0043318; P:negative regulation of cytotoxic T cell degranulation; ISS:UniProtKB.
DR   GO; GO:0045717; P:negative regulation of fatty acid biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0030853; P:negative regulation of granulocyte differentiation; ISS:UniProtKB.
DR   GO; GO:2000346; P:negative regulation of hepatocyte proliferation; IMP:UniProtKB.
DR   GO; GO:0032692; P:negative regulation of interleukin-1 production; ISS:UniProtKB.
DR   GO; GO:0051055; P:negative regulation of lipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0002859; P:negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target; ISS:UniProtKB.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; ISO:RGD.
DR   GO; GO:0090331; P:negative regulation of platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; ISS:UniProtKB.
DR   GO; GO:0001915; P:negative regulation of T cell mediated cytotoxicity; ISS:UniProtKB.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; ISO:RGD.
DR   GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043116; P:negative regulation of vascular permeability; ISS:UniProtKB.
DR   GO; GO:1903387; P:positive regulation of homophilic cell adhesion; IDA:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:MGI.
DR   GO; GO:2001214; P:positive regulation of vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0060312; P:regulation of blood vessel remodeling; ISS:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0030334; P:regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0045601; P:regulation of endothelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0010594; P:regulation of endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0042058; P:regulation of epidermal growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:1903385; P:regulation of homophilic cell adhesion; IDA:UniProtKB.
DR   GO; GO:0002682; P:regulation of immune system process; IBA:GO_Central.
DR   GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB.
DR   GO; GO:1903670; P:regulation of sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   GO; GO:0044319; P:wound healing, spreading of cells; ISS:UniProtKB.
DR   CDD; cd20948; IgC2_CEACAM5-like; 1.
DR   CDD; cd05740; IgI_hCEACAM_2_4_6_like; 2.
DR   CDD; cd05774; IgV_CEACAM_D1; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 4.
DR   InterPro; IPR050831; CEA_cell_adhesion.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013106; Ig_V-set.
DR   PANTHER; PTHR44427:SF1; CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 1; 1.
DR   PANTHER; PTHR44427; CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 19; 1.
DR   Pfam; PF13895; Ig_2; 1.
DR   Pfam; PF13927; Ig_3; 2.
DR   Pfam; PF07686; V-set; 1.
DR   SMART; SM00409; IG; 4.
DR   SMART; SM00408; IGc2; 3.
DR   SUPFAM; SSF48726; Immunoglobulin; 4.
DR   PROSITE; PS50835; IG_LIKE; 3.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell adhesion; Cell junction; Cell membrane;
KW   Cell projection; Cytoplasmic vesicle; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Immunoglobulin domain; Membrane;
KW   Phosphoprotein; Pyrrolidone carboxylic acid; Reference proteome; Repeat;
KW   Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..34
FT                   /evidence="ECO:0000255"
FT   CHAIN           35..519
FT                   /note="Carcinoembryonic antigen-related cell adhesion
FT                   molecule 1"
FT                   /id="PRO_0000014564"
FT   TOPO_DOM        35..425
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        426..446
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        447..519
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          42..140
FT                   /note="Ig-like V-type"
FT                   /evidence="ECO:0000250|UniProtKB:P31997"
FT   DOMAIN          147..232
FT                   /note="Ig-like C2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DOMAIN          237..317
FT                   /note="Ig-like C2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DOMAIN          325..403
FT                   /note="Ig-like C2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   REGION          39..142
FT                   /note="Required for homophilic binding"
FT                   /evidence="ECO:0000269|PubMed:8831574"
FT   REGION          445..457
FT                   /note="Interaction with calmodulin"
FT                   /evidence="ECO:0000269|PubMed:8576129"
FT   REGION          447..519
FT                   /note="Interaction with FLNA"
FT                   /evidence="ECO:0000269|PubMed:16291724"
FT   REGION          455..519
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          484..519
FT                   /note="Required for interaction with PTPN11 and PTPN6 and
FT                   for control of phosphorylation level"
FT                   /evidence="ECO:0000250|UniProtKB:P31809"
FT   REGION          513..516
FT                   /note="Essential for interaction with PTPN11 and PTPN6"
FT                   /evidence="ECO:0000250|UniProtKB:P31809"
FT   COMPBIAS        467..513
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         35
FT                   /note="Pyrrolidone carboxylic acid"
FT                   /evidence="ECO:0000250|UniProtKB:P13688"
FT   MOD_RES         488
FT                   /note="Phosphotyrosine; by SRC, LCK, INSR and EGFR"
FT                   /evidence="ECO:0000269|PubMed:15467833,
FT                   ECO:0000269|PubMed:16054098, ECO:0000269|PubMed:7518458,
FT                   ECO:0000269|PubMed:7626603, ECO:0000269|PubMed:9712832"
FT   MOD_RES         503
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16054098,
FT                   ECO:0000269|PubMed:7518458"
FT   MOD_RES         513
FT                   /note="Phosphotyrosine; by INSR, SRC and LCK"
FT                   /evidence="ECO:0000269|PubMed:16054098"
FT   CARBOHYD        87
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        104
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        113
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        148
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        152
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        173
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        197
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        224
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        256
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        288
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        292
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        302
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        315
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        331
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        374
FT                   /note="N-linked (GlcNAc...) asparagine; atypical"
FT                   /evidence="ECO:0000250|UniProtKB:P31809,
FT                   ECO:0000255|PROSITE-ProRule:PRU00498"
FT   DISULFID        167..215
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        259..299
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        344..392
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         455..458
FT                   /note="GSDH -> SGSF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1637321,
FT                   ECO:0000303|PubMed:8504806, ECO:0000303|PubMed:8536699"
FT                   /id="VSP_002504"
FT   VAR_SEQ         459..519
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1637321,
FT                   ECO:0000303|PubMed:8504806, ECO:0000303|PubMed:8536699"
FT                   /id="VSP_002505"
FT   VARIANT         49
FT                   /note="K -> S (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         55
FT                   /note="A -> T (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         70
FT                   /note="G -> V (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         73
FT                   /note="L -> T (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         74
FT                   /note="N -> G (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         75
FT                   /note="P -> L (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         76
FT                   /note="D -> N (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         86
FT                   /note="D -> S (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         88
FT                   /note="M -> T (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         90
FT                   /note="K -> Q (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         92
FT                   /note="G -> E (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         99
FT                   /note="E -> V (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         118
FT                   /note="R -> G (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         119
FT                   /note="A -> P (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         125
FT                   /note="F -> I (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   VARIANT         127
FT                   /note="Q -> K (in allele b)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1637321, ECO:0000269|PubMed:8504806"
FT   MUTAGEN         488
FT                   /note="Y->F: Phosphorylated on serine. Decreases bile acid
FT                   transport Doesn't phosphorylated by EGFR. Doesn't increase
FT                   interaction with SHC1. Completely inhibits insulin-
FT                   stimulated phosphorylation. No effect on INSR
FT                   internalization and INS degradation. Prevents CEACAM1
FT                   phosphorylation and the increase in its binding to FASN in
FT                   the presence of INSR. No effect on cell-surface expression
FT                   in response to INS. Abolishes phosphorylation by INSR.
FT                   Abolishes indirect interaction with INSR."
FT                   /evidence="ECO:0000269|PubMed:15467833,
FT                   ECO:0000269|PubMed:16054098, ECO:0000269|PubMed:7518458,
FT                   ECO:0000269|PubMed:7592607, ECO:0000269|PubMed:7626603,
FT                   ECO:0000269|PubMed:9712832"
FT   MUTAGEN         502..503
FT                   /note="TS->AA: Phosphorylated on tyrosine. Impairs bile
FT                   acid transport."
FT                   /evidence="ECO:0000269|PubMed:7518458"
FT   MUTAGEN         503
FT                   /note="S->A: Abolishes phosphorylation by EGFR. Reduces
FT                   interaction with SHC1. Completely inhibits insulin-
FT                   stimulated phosphorylation. No effect on INSR
FT                   internalization and INS degradation. In L-SACC1; completely
FT                   inhibits insulin-stimulated phosphorylation; develops
FT                   hyperinsulinemia resulting from impaired insulin clearance;
FT                   the hyperinsulinemia causes secondary insulin resistance
FT                   with impaired glucose tolerance and random, but not
FT                   fasting, hyperglycemia; insulin doesn't significantly
FT                   decrease FASN activity in liver. Prevents CEACAM1
FT                   phosphorylation and the increase in its binding to FASN in
FT                   the presence of INSR. No effect on cell-surface expression
FT                   in response to INS."
FT                   /evidence="ECO:0000269|PubMed:11694516,
FT                   ECO:0000269|PubMed:11850617, ECO:0000269|PubMed:15467833,
FT                   ECO:0000269|PubMed:16054098, ECO:0000269|PubMed:7592607,
FT                   ECO:0000269|PubMed:7626603, ECO:0000269|PubMed:9712832"
FT   MUTAGEN         503
FT                   /note="S->D: Preserves the ability of INSR to induce
FT                   CEACAM1 phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:16054098"
FT   MUTAGEN         513
FT                   /note="Y->F: Increases INSR internalization and INS
FT                   degradation. Phosphorylated by INSR. Prevents the increase
FT                   in CEACAM1 binding to FASN by INSR. Decreases cell-surface
FT                   expression in response to INS. Doesn't affect
FT                   phosphorylation by INSR."
FT                   /evidence="ECO:0000269|PubMed:16054098,
FT                   ECO:0000269|PubMed:7592607, ECO:0000269|PubMed:9712832"
SQ   SEQUENCE   519 AA;  57410 MW;  9EFE74FD565E7C29 CRC64;
     MELASARLLR GQIPWRGLLL TASLLTYWSP LTTAQVTVDA VPPNVVEEKS VLLLAHNLPQ
     EFQVFYWYKG TTLNPDSEIA RYIRSDNMSK TGPAYSGRET IYSNGSLFFQ NVNKTDERAY
     TLSVFDQQFN PIQTSVQFRV YPALQKPNVT GNNSNPMEGE PFVSLMCEPY TNNTSYLWSR
     NGESLSEGDR VTFSEGNRTL TLLNVRRTDK GYYECEARNP ATFNRSDPFN LDVIYGPDAP
     VISPPDIYLH QGSNLNLSCH ADSNPPAQYF WLINEKLQTS SQELFISNIT TNNSGTYACF
     VNNTVTGLSR TTVKNITVFE PVTQPSIQIT NTTVKELGSV TLTCFSKDTG VSVRWLFNSQ
     SLQLTDRMTL SQDNSTLRID PIKREDAGDY QCEISNPVSF RISHPIKLDV IPDPTQGNSG
     LSEGAIAGIV IGSVAGVALI AALAYFLYSR KTGGGSDHRD LTEHKPSTSS HNLGPSDDSP
     NKVDDVSYSV LNFNAQQSKR PTSASSSPTE TVYSVVKKK
//
